SCHEMBL5026959

SCHEMBL5026959

OCCNc1cc(Cl)ncn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.54
CYP2C19 P33261 1/20 0.54
EGFR P00533 3/20 0.48
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 1/20 0.39
MAP4K4 O95819 3/20 0.39
TYK2 P29597 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
MINK1 Q8N4C8 1/20 0.39
SRPK1 Q96SB4 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
CHEK1 O14757 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
KDM4D Q6B0I6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28158644 0.81 DNM2 (0.45) CYP2D6CYP2C19EGFRMEN1KMT2A
SCHEMBL9181933 0.78 DNM2 (0.54) EGFRMEN1KMT2ANPSR1NPC1
SCHEMBL17728852 0.78 DNM2 (0.57) EGFRNPC1KDM4EPOLBMAPT
SCHEMBL29402899 0.77 EGFR (0.51) CYP2D6CYP2C19EGFRNPSR1MAP4K4
SCHEMBL16840824 0.77 EGFR (0.55) CYP2D6CYP2C19EGFRMEN1KMT2A
SCHEMBL11981509 0.77 EGFR (0.55) CYP2D6CYP2C19EGFRMEN1KMT2A
SCHEMBL807297 0.77 EGFR (0.51) CYP2D6CYP2C19EGFRNPSR1MAP4K4
SCHEMBL19489281 0.77 EGFR (0.48) CYP2D6CYP2C19EGFRMEN1KMT2A
SCHEMBL16656099 0.77 CYP1A2 (0.54) CYP2D6CYP2C19MEN1KMT2ANPC1
SCHEMBL20081779 0.77 HRH3 (0.44) CYP2D6CYP2C19EGFRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023146512-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146512-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
EP-2339351-A1 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2011-06-29 EP disclosed
CN-101438288-A Regulation of phosphoryl transferase activity of glutamine synthetase CSIR CORP (ZA) 2009-05-20 CN disclosed
EP-2008210-A1 MODULATION OF PHOSPHORYL TRANSFERASE ACTIVITY OF GLUTAMINE SYNTHETASE CSIR (ZA) 2008-12-31 EP disclosed
WO-2007105023-A1 MODULATION OF PHOSPHORYL TRANSFERASE ACTIVITY OF GLUTAMINE SYNTHETASE CSIR (ZA) 2007-09-20 WO disclosed
EP-0004173-B1 2,3-DIHYDROIMIDAZO (1,2-C) PYRIMIDINES, THEIR PREPARATION, FORMULATIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS ELI LILLY AND COMPANY (US) 1982-09-22 EP disclosed
EP-0004173-A1 2,3-Dihydroimidazo (1,2-c) pyrimidines, their preparation, formulations containing them and their use as pharmaceuticals ELI LILLY AND COMPANY (US) 1979-09-19 EP disclosed
US-4153695-A VIRICIDES ELI LILLY AND COMPANY (US) 1979-05-08 US disclosed